Could stem cell secretions protect hearing during implant surgery?

NCT ID NCT06545175

Ongoing Disease control Sponsor: Hannover Medical School Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This early-stage trial tests whether a substance called VSF1.01, made from stem cell secretions, can safely reduce trauma to the inner ear during cochlear implant surgery. Eleven adults with severe hearing loss will receive the treatment directly into the cochlea before the implant is placed. The study primarily checks for side effects, and also looks at whether it helps preserve nerve responses and improve speech understanding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VSF1.01 (a solution enriched with extracellular vesicles from human umbilical cord mesenchymal stem cells)
What this could lead to: If successful, this could lead to a treatment that reduces inner ear damage during cochlear implant surgery, potentially improving hearing outcomes.
What could go wrong: This is an early-phase trial with only 11 participants, so results may not apply to everyone. The treatment is new and its safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEARING LOSS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hearing loss disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEARING LOSS

Contacts and locations

Locations

Hannover Medical School, Dept. of Otorhinolaryngology

Hanover, 30625, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.